Valeant hands off its controversial, $1B female libido drug to Sprout backers in sweetheart deal
A little more than 2 years ago, Valeant agreed to buy Sprout Pharmaceuticals and its controversial female libido drug Addyi for a cool $1 billion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
